Abstract
This survey study investigates whether cannabis use is associated with risk of diabetic ketoacidosis in adults with type 1 diabetes.
Cannabis use is increasing with the shifts in legality and public perceptions in the United States.1 Studies have reported improvement in insulin sensitivity and pancreatic beta cell function with cannabis use,2,3 generating widespread media attention suggesting cannabis as a potential therapeutic agent for treatment of type 2 diabetes. By contrast, we published a case series4 reporting recurrent diabetic ketoacidosis (DKA) with cannabis use in patients with type 1 diabetes (T1D). Because little is known about cannabis use and its contribution to DKA in T1D, we investigated the characteristics of cannabis use among adults with T1D and the association of cannabis use with DKA.
Methods
Between June 2017 and January 2018, adults aged 18 years or older with T1D attending the Barbara Davis Center for Diabetes, the largest T1D treatment center in Colorado, where cannabis is legal for medical and recreational use, were invited to complete an in-person questionnaire on their cannabis use. Patients with diabetes other than T1D, pregnancy, and repeat follow-up visits within the study duration were excluded. A questionnaire was used to collect demographic characteristics, diabetes history and complications, severe hypoglycemia requiring assistance, and cannabis use information. Point-of-care hemoglobin A1c level (HbA1c; DCA Vantage Analyzer) was measured during the clinic visit. Scores on the Cannabis Use Disorder Identification Test-Revised5 were used to define hazardous cannabis use (score ≥8 and <12) and possible cannabis use disorder (score ≥12). The Colorado Multiple Institutional Review Board (Aurora, Colorado) approved this study, and all participants provided written informed consent.
The primary outcome was DKA hospitalization during the preceding 12 months. All self-reported DKA hospitalizations were confirmed by medical record review. Comparison of categorical variables was conducted with 2-tailed χ2 tests, and 2-sample t tests were used to test normally distributed continuous variables. A logistic regression model was built to calculate the odds of DKA hospitalization by cannabis use. Clinical evidence-based risk factors for DKA, such as age, sex, diabetes duration, income, educational level, HbA1c level, and insurance (derived from income), were modeled, and a stepwise selection method was used to confirm the final model. Model fit was assessed by Akaike information criterion. Sensitivity analyses were performed using propensity score matching of cannabis users and nonusers, adjusting for age, sex, ethnicity, tobacco and alcohol use, educational level, income, employment, diabetes duration, HbA1c level, and use of diabetes technology. Residual confounding was controlled by including significant variables in the final logistic regression model. All analyses were conducted using SAS, version 9.4 (SAS Institute Inc). A 2-sided P < .05 was considered statistically significant.
Results
Of the 631 eligible patients, 450 (71.3%) responded to the survey. The mean (SD) age (36.8 [13.8] vs 34.6 [11.9] years, P = .07), sex (female, 201 [44.6%] vs 86 [47.5%]; P = .10), mean (SD) diabetes duration (19.5 [12.9] vs 18.3 [12.1] years, P = .22) and mean (SD) HbA1c level as percent of total hemoglobin (7.8% [1.8%] vs 7.8% [1.2%], P = .72; to convert HbA1c to proportion of total hemoglobin, multiply by 0.01) were similar between responders and nonresponders. Among 450 T1D participants, 134 (29.8%) reported using cannabis. Cannabis use duration, frequency, and form are shown in Table 1. Cannabis users were younger (entire cohort mean [SD] age, 31.3 [11.1] vs 39.1 [14.2] years), had lower income and educational levels, and shorter duration of diabetes (entire cohort mean [SD] duration, 16.3 [11.2] vs 20.9 [13.6] years) than nonusers (Table 1).
Table 1. Characteristics of Adults With Type 1 Diabetes by Cannabis Use.
| Characteristic | Adults With Type 1 Diabetes, No. (%) | |||||
|---|---|---|---|---|---|---|
| Entire Cohort (n = 450) | Matched Cohort (n = 202)a | |||||
| Cannabis User (n = 134) | Cannabis Nonuser (n = 316) | Standardized Difference, %b | Cannabis User (n = 101) | Cannabis Nonuser (n = 101) | Standardized Difference, %b | |
| Age, mean (SD), y | 31.3 (11.1) | 39.1 (14.2) | −61.2 | 34.5 (12.3) | 35.7 (14.2) | −9 |
| Female | 74 (55.2) | 127 (40.2) | 30.4 | 54 (53.4) | 47 (46.5) | 13.8 |
| Race/ethnicityc | ||||||
| Non-Hispanic white | 118 (88.1) | 281 (88.9) | −2.5 | 90 (89.1) | 89 (88.1) | 3.1 |
| Other | 15 (11.2) | 33 (10.4) | 2.6 | 11 (10.9) | 12 (11.9) | −3.1 |
| Cigarette smoking status | ||||||
| Never | 68 (50.7) | 243 (76.9) | −56.7 | 55 (54.5) | 69 (68.3) | −28.6 |
| Former | 41 (30.6) | 61 (19.3) | 26.3 | 28 (27.7) | 23 (22.7) | 11.5 |
| Current | 24 (17.9) | 10 (3.2) | 49.2 | 18 (17.8) | 9 (8.9) | 26.4 |
| Alcohol use, drinks/wk | ||||||
| Never | 19 (14.2) | 86 (27.2) | −32.5 | 19 (18.8) | 24 (23.8) | −12.2 |
| <3 | 44 (32.8) | 56 (17.8) | 35.0 | 29 (28.7) | 21 (20.8) | 18.4 |
| >3 | 69 (51.5) | 172 (54.4) | −5.8 | 52 (51.5) | 56 (55.4) | −7.8 |
| Educational level | ||||||
| High school degree or some high school | 61 (45.5) | 73 (23.1) | 48.6 | 44 (43.6) | 37 (36.6) | 14.3 |
| College degree | 57 (42.5) | 173 (54.7) | −24.6 | 44 (43.6) | 46 (45.5) | −3.82 |
| Graduate degree | 16 (12.0) | 67 (21.2) | −24.9 | 13 (12.9) | 18 (17.8) | −13.6 |
| Income, $ | ||||||
| <50 000 | 89 (66.4) | 132 (41.8) | 50.9 | 51 (50.5) | 42 (41.6) | 17.9 |
| 50 000-100 000 | 25 (18.7) | 107 (33.9) | −35.1 | 38 (37.6) | 37 (36.6) | 2.1 |
| >100 000 | 15 (11.2) | 65 (20.6) | −25.9 | 11 (10.9) | 16 (15.8) | −14.4 |
| Employment | ||||||
| Full-time | 69 (51.5) | 194 (61.4) | −20.1 | 59 (58.4) | 66 (65.3) | −14.2 |
| Part-time | 14 (10.4) | 39 (12.3) | −5.9 | 10 (9.9) | 8 (7.9) | 7.0 |
| Student | 15 (11.2) | 24 (7.6) | 12.4 | 10 (9.9) | 6 (5.9) | 14.9 |
| Part-time and student | 8 (6.0) | 9 (2.9) | 15.1 | 5 (4.9) | 4 (3.9) | −4.8 |
| Unemployed | 26 (19.4) | 45 (14.2) | 13.9 | 17 (16.8) | 16 (15.8) | 2.7 |
| Diabetes duration, mean (SD), y | 16.3 (11.2) | 20.9 (13.6) | −36.9 | 17.5 (12.4) | 18.7 (13.7) | −9.2 |
| HbA1c, mean (SD), % of total hemoglobin | 8.4 (2.0) | 7.6 (1.6) | 44.2 | 8.3 (2.1) | 7.9 (1.7) | 20.9 |
| Diabetes technology used | ||||||
| Continuous glucose monitoring | 61 (45.5) | 174 (55.1) | −19.7 | 46 (45.5) | 49 (48.5) | −6.0 |
| Insulin pump | 68 (50.7) | 210 (66.5) | −32.5 | 45 (44.6) | 41 (40.6) | 8.1 |
| DKA hospitalization | 28 (20.9) | 26 (8.2) | 36.6 | 22 (21.8) | 8 (7.9) | 39.8 |
| Severe hypoglycemia | 21 (15.6) | 64 (20.3) | −12.3 | 16 (15.8) | 18 (17.8) | −5.3 |
| Forms of cannabis usee | ||||||
| Smoking | 97 (72.4) | 80 (79.2) | ||||
| Edible | 65 (48.5) | 53 (52.4) | ||||
| Vaporization | 54 (40.3) | 44 (43.6) | ||||
| Other | 19 (14.2) | 10 (9.9) | ||||
| Cannabis use frequencyf | ||||||
| ≤1 time/mo | 48 (35.8) | 27 (26.7) | ||||
| 2-4 times/mo | 14 (10.4) | 10 (9.9) | ||||
| 2-3 times/wk | 17 (12.7) | 14 (13.9) | ||||
| ≥4 times/wk | 54 (40.3) | 50 (59.5) | ||||
| Cannabis use duration, y | ||||||
| <0.5 | 13 (9.7) | 0 | ||||
| 0.5-1 | 16 (11.9) | 0 | ||||
| 1-3 | 30 (22.4) | 30 (29.7) | ||||
| >3 | 71 (53.0) | 71 (70.3) | ||||
| Reasons for cannabis usee | ||||||
| Recreation | 101 (75.4) | 79 (78.2) | ||||
| Medical (diabetes related) | 24 (17.9) | 21 (20.8) | ||||
| Medical (nondiabetes related) | 34 (25.4) | 28 (27.7) | ||||
| CUDIT-R score | ||||||
| No hazardous use | 78 (58.2) | 51 (50.5) | ||||
| Hazardous cannabis use | 32 (23.9) | 27 (26.7) | ||||
| Possible cannabis use disorder | 24 (17.9) | 23 (22.7) | ||||
Abbreviations: CUDIT-R, Cannabis Use Disorder Identification Test-Revised; DKA, diabetic ketoacidosis; HbA1c, hemoglobin A1c.
SI conversion: To convert HbA1c to proportion of total hemoglobin, multiply by 0.01.
Only participants using cannabis for more than 12 months were matched for noncannabis users using propensity score.
Standardized differences (cannabis users vs nonusers) are reported as percentages, with a difference of less than 10% indicating a negligible imbalance.
Race/ethnicity was self-reported.
Many participants reported using both insulin pump and continuous glucose monitoring.
Some participants answered with more than 1 reason or form of cannabis use.
Cannabis use frequency was derived from CUDIT-R questionnaire.
In adults with T1D, cannabis use within the previous 12 months was associated with an increased risk of DKA compared with no cannabis use (entire cohort OR, 1.98; 95% CI, 1.01-3.91) (Table 2). Compared with nonusers with T1D, the mean (SD) HbA1c level (8.4% [2.0%] vs 7.6% [1.6%], P < .01) was higher but there was no difference in severe hypoglycemia (21 of 134 [15.6%] vs 64 of 316 [20.3%], P = .17) among cannabis users with T1D. Cannabis users had a mean 0.41% higher HbA1c level than nonusers when adjusted for insulin delivery method, income, and age (β, 0.41; 95% CI, 0.38-0.43).
Table 2. Primary Outcome of Diabetic Ketoacidosis in the Previous 12 Months Among Cannabis Users vs Nonusers With Type 1 Diabetes.
| Variable | Odds Ratio (95% CI) | |
|---|---|---|
| Entire Cohort (n = 421) | Matched Cohort (n = 202) | |
| Cannabis use within last 12 mo | 1.98 (1.01-3.91) | 3.06 (1.03-9.19) |
| Duration of diabetes | 0.98 (0.93-1.01) | 0.94 (0.89-0.99) |
| HbA1c level | 1.2 (1.03-1.41) | 1.15 (0.94-1.41) |
| Income, $ | ||
| <50 000 vs >100 000 | 3.62 (1.29-9.76) | 1.19 (0.22-6.22) |
| 50 000-100 000 vs >100 000 | 1.42 (0.29-6.14) | 0.45 (0.06-3.22) |
Abbreviation: HbA1C, hemoglobin A1c.
Discussion
In the present survey study, the prevalence of cannabis use was 30% among adults with T1D. Cannabis use was associated with a higher risk for DKA in this population. Cannabinoids alter gut motility and cause hyperemesis, which may play a role in increased risk for DKA in T1D.4,6 A small sample size, single-center, and self-reported diabetes outcomes are limitations of the present study. The possibility of unmeasured confounders, such as access to health care, cannot be excluded. Further research is needed to confirm these findings and understand the effects and adverse consequences of cannabis use in patients with T1D.
References
- 1.Hasin DS, Sarvet AL, Cerdá M, et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 2017;74(6):579-588. doi: 10.1001/jamapsychiatry.2017.0724 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39(10):1777-1786. doi: 10.2337/dc16-0650 [DOI] [PubMed] [Google Scholar]
- 3.Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Am J Med. 2013;126(7):583-589. doi: 10.1016/j.amjmed.2013.03.002 [DOI] [PubMed] [Google Scholar]
- 4.Gallo T, Shah VN. An unusual cause of recurrent diabetic ketoacidosis in type 1 diabetes. Am J Med. 2016;129(8):e139-e140. doi: 10.1016/j.amjmed.2016.02.033 [DOI] [PubMed] [Google Scholar]
- 5.Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend. 2010;110(1-2):137-143. doi: 10.1016/j.drugalcdep.2010.02.017 [DOI] [PubMed] [Google Scholar]
- 6.Monte AA, Zane RD, Heard KJ. The implications of marijuana legalization in Colorado. JAMA. 2015;313(3):241-242. doi: 10.1001/jama.2014.17057 [DOI] [PMC free article] [PubMed] [Google Scholar]
